VJHemOnc is committed to improving our service to you

MDS 2020 | Role of hypomethylating agents in the novel agent era

VJHemOnc is committed to improving our service to you

Moshe Mittelman

Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, discusses the current and future role of hypomethylating agents in the treatment of myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter